查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606914

癌症診斷人工智慧的全球市場（按組成部分、按癌症類型、按最終用戶、按地區（北美、歐洲、亞太地區、拉丁美洲、中東和非洲））：趨勢分析、競爭格局、未來預測（2019年） -2030)

AI in Cancer Diagnostics Market, By Component; By Cancer Type; By End User; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa ), Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 521 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球癌症診斷人工智慧市場將擴大八倍，到 2030 年達到 50 億美元。

由於技術進步、癌症發病率上升以及對早期檢測和個人化醫療的需求不斷成長，全球癌症診斷人工智慧市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2023 年全球癌症診斷人工智慧市場以金額為準將達到 6.433 億美元。 BlueWeave 預測，在 2024 年至 2030 年的預測期內，全球癌症診斷人工智慧市場規模將以 34.60% 的複合年成長率強勁成長，到 2030 年達到 50.949 億美元。機器學習演算法和成像技術的進步推動了用於癌症診斷的人工智慧的全球市場，這些技術可以實現更快、更準確的癌症檢測。全球癌症盛行率不斷上升，加上對個人化治療的需求不斷成長，正在推動人工智慧的採用。將人工智慧與 MRI 和電腦斷層掃描等影像方式結合將提高診斷準確性。政府對醫療保健領域人工智慧的支持和資助，以及科技公司和醫療機構之間的夥伴關係將進一步推動市場成長。成本效率和診斷錯誤的減少將推動全球癌症診斷人工智慧市場的快速成長。

機會 - 日益關注診斷和成本效率

採用人工智慧進行癌症診斷可以提高診斷準確性，加快醫療資料分析速度，並更快獲得結果。人工智慧驅動的工具可以比傳統方法更快地處理大量資料和遺傳資料，從而減少手動解釋的需要。這種效率不僅可以改善患者的治療效果，還可以降低醫療保健提供者的營運成本，使先進的診斷更容易獲得和負擔得起，並推動癌症診斷市場的成長。

地緣政治緊張局勢加劇對全球癌症診斷人工智慧市場的影響

不斷升級的地緣政治緊張局勢可能會阻礙跨境合作、減緩技術進步並限制對重要資料和研究的獲取，從而擾亂全球癌症診斷人工智慧市場。貿易限制可能會減緩人工智慧主導的診斷工具的開發，緊張的國際關係可能會影響投資和資金籌措。此外，不同地區的監管挑戰可能會使市場成長更加複雜，減少癌症診斷人工智慧解決方案的採用，並影響全球醫療保健的普及。

軟體解決方案領域引領全球癌症診斷人工智慧市場

軟體解決方案領域是全球癌症診斷人工智慧市場的關鍵組成部分。擴大使用人工智慧主導的診斷工具來提高診斷準確性和效率，例如影像分析、生物標記檢測和風險評估，正在推動人工智慧引領市場。將先進演算法融入醫療平台，加上對軟體進步的投資增加，在提高市場佔有率方面發揮關鍵作用。此外，我們針對多種癌症類型的軟體解決方案的擴充性和成本效益進一步鞏固了我們的市場優勢。

競爭格局

全球癌症診斷人工智慧市場競爭激烈，許多企業爭奪更大的市場佔有率。市場主要企業包括Ibex Medical Analytics、Paige AI、PathAI、Tempus、Freenome、Enlitic、CureMetrix、Owkin、DeepBio、AIRA Matrix、Indica Labs、Mindpeak等。這些公司正在利用各種策略，包括增加研發活動併購、合資、聯盟、許可協議以及發布新產品和服務，以進一步主導全球癌症診斷人工智慧市場。

該報告的詳細分析提供了全球癌症診斷人工智慧市場的成長潛力、未來趨勢和統計資訊。它還重點關注推動市場總規模預測的因素。該報告致力於提供全球癌症診斷人工智慧市場的最新技術趨勢和產業見解，幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 分析框架

第 2 章執行摘要

第3章市場考察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 提高診斷準確性
      • 早期發現與預防
      • 個人化醫療
    • 抑制因素
      • 資料品質和數量
      • 道德考慮和偏見
    • 機會
      • 提高效率並降低成本
      • 增加投資和監管支持
    • 任務
      • 實施成本高
      • 缺乏臨床檢驗和招募
  • 科技進步/最新趨勢
  • 法規結構
  • 波特五力分析

第4章 全球癌症診斷人工智慧市場：行銷策略

第5章 全球癌症診斷人工智慧市場：區域分析

  • 全球癌症診斷人工智慧市場：區域分析（2023）
  • 全球癌症診斷人工智慧市場：市場魅力分析（2024-2030）

第6章全球癌症診斷人工智慧市場：概述

  • 市場規模及預測（2019-2030）
    • 以金額為準
  • 市場佔有率及預測
    • 按成分
      • 軟體解決方案
      • 硬體
      • 服務
    • 按癌症類型
      • 乳癌
      • 肺癌
      • 攝護腺癌
      • 大腸直腸癌
      • 腦腫瘤
      • 其他
    • 按最終用戶
      • 醫院
      • 手術中心/醫療機構
      • 其他
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第7章 北美癌症診斷人工智慧市場

  • 市場規模及預測（2019-2030）
    • 以金額為準
  • 市場佔有率及預測
    • 按成分
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第8章歐洲癌症診斷人工智慧市場

  • 市場規模及預測（2019-2030）
    • 以金額為準
  • 市場佔有率及預測
    • 按成分
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第9章 亞太地區癌症診斷人工智慧市場

  • 市場規模及預測（2019-2030）
    • 以金額為準
  • 市場佔有率及預測
    • 按成分
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲/紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第10章拉丁美洲癌症診斷人工智慧市場

  • 市場規模及預測（2019-2030）
    • 以金額為準
  • 市場佔有率及預測
    • 按成分
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第11章：中東和非洲癌症診斷的人工智慧市場

  • 市場規模及預測（2019-2030）
    • 以金額為準
  • 市場佔有率及預測
    • 按成分
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第12章競爭格局

  • 主要企業及其產品列表
  • 全球癌症診斷人工智慧公司：市場佔有率分析（2023）
  • 競爭基準：按管理參數
  • 主要策略（企業合併、業務聯盟）發展現狀

第13章 全球癌症診斷人工智慧市場：進口/出口

第14章 地緣政治緊張局勢加劇對全球癌症診斷人工智慧市場的影響

第15章 公司簡介（公司概況、財務矩陣、競爭格局、公司負責人、主要競爭對手、聯絡方式、策略展望）

  • Ibex Medical Analytics
  • Paige AI
  • PathAI
  • Tempus
  • Freenome
  • Enlitic
  • CureMetrix
  • Owkin
  • DeepBio
  • AIRA Matrix
  • Indica Labs
  • Mindpeak
  • 其他主要企業

第16章 主要策略建議

第17章分析技術

簡介目錄
Product Code: BWC24905

Global AI in Cancer Diagnostics Market Size Zooms 8X to Surpass USD 5 Billion by 2030

Global AI in Cancer Diagnostics Market is thriving due to technological advancements, rising cancer prevalence, and a spurring demand for early detection and personalized medicine.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global AI in Cancer Diagnostics Market size by value at USD 643.3 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global AI in Cancer Diagnostics Market size to expand at a robust CAGR of 34.60% reaching a value of USD 5,094.9 million by 2030. Global AI in Cancer Diagnostics Market is driven by advancements in machine learning algorithms and imaging technologies, enabling faster and more accurate cancer detection. Increasing cancer prevalence across the world, coupled with rising demand for personalized treatment, fuels AI adoption. Integration of AI with imaging modalities like MRI and CT scans enhances diagnostic precision. Supportive government initiatives and funding for AI in healthcare, along with partnerships between tech firms and medical institutions, further propel market growth. Cost efficiency and reduced diagnostic errors add momentum to the rapid growth of Global AI in Cancer Diagnostics Market.

Opportunity -Increasing Focus on Diagnostic and Cost Efficiency

The adoption of AI in cancer diagnostics enhances diagnostic accuracy and speeds up the analysis of medical data, leading to quicker results. AI-powered tools can process vast amounts of imaging and genetic data faster than traditional methods, reducing the need for manual interpretation. This efficiency improves patient outcomes and also lowers operational costs for healthcare providers, making advanced diagnostics more accessible and affordable, which is driving market growth in cancer diagnostics.

Impact of Escalating Geopolitical Tensions on Global AI in Cancer Diagnostics Market

Escalating geopolitical tensions could disrupt Global AI in Cancer Diagnostics Market by hindering cross-border collaborations, slowing technological advancements, and limiting access to essential data and research. Trade restrictions may delay the development of AI-driven diagnostic tools, while strained international relations can impact investments and funding. Additionally, regulatory challenges across different regions could further complicate market growth, potentially reducing the adoption of AI solutions in cancer diagnostics and affecting healthcare accessibility globally.

Software Solutions Segment Leads Global AI in Cancer Diagnostics Market

The software solutions segment stands out as the leading component of Global AI in Cancer Diagnostics Market. The market leadership position of AI is fueled by the rising use of AI-driven diagnostic tools for tasks, such as image analysis, biomarker detection, and risk evaluation, which improve both diagnostic precision and efficiency. The incorporation of sophisticated algorithms into healthcare platforms, coupled with increased investments in software advancements, plays a crucial role in boosting its market share. Additionally, the scalability and cost-effectiveness of software solutions across various cancer types further solidify their dominant position in the market.

Competitive Landscape

Global AI in Cancer Diagnostics Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Ibex Medical Analytics, Paige AI, PathAI, Tempus, Freenome, Enlitic, CureMetrix, Owkin, DeepBio, AIRA Matrix, Indica Labs, and Mindpeak. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global AI in Cancer Diagnostics Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global AI in Cancer Diagnostics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global AI in Cancer Diagnostics Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global AI in Cancer Diagnostics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Enhanced Diagnostic Accuracy
      • 3.2.1.2. Early Detection and Prevention
      • 3.2.1.3. Personalized Medicine
    • 3.2.2. Restraints
      • 3.2.2.1. Data Quality and Quantity
      • 3.2.2.2. Ethical Considerations and Bias
    • 3.2.3. Opportunities
      • 3.2.3.1. Increased Efficiency and Reduced Costs
      • 3.2.3.2. Growing Investment and Regulatory Support
    • 3.2.4. Challenges
      • 3.2.4.1. High Cost of Implementation
      • 3.2.4.2. Lack of Clinical Validation and Adoption
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global AI in Cancer Diagnostics Market: Marketing Strategies

5. Global AI in Cancer Diagnostics Market: Geographical Analysis

  • 5.1. Global AI in Cancer Diagnostics Market, Geographical Analysis, 2023
  • 5.2. Global AI in Cancer Diagnostics Market, Market Attractiveness Analysis, 2024-2030

6. Global AI in Cancer Diagnostics Market Overview

  • 6.1. Market Size & Forecast, 2019-2030
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
      • 6.2.1.1. Software Solutions
      • 6.2.1.2. Hardware
      • 6.2.1.3. Services
    • 6.2.2. By Cancer Type
      • 6.2.2.1. Breast Cancer
      • 6.2.2.2. Lung Cancer
      • 6.2.2.3. Prostate Cancer
      • 6.2.2.4. Colorectal Cancer
      • 6.2.2.5. Brain Tumor
      • 6.2.2.6. Others
    • 6.2.3. By End User
      • 6.2.3.1. Hospitals
      • 6.2.3.2. Surgical Centers & Medical Institutes
      • 6.2.3.3. Others
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America AI in Cancer Diagnostics Market

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Cancer Type
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Component
      • 7.2.4.1.2. By Cancer Type
      • 7.2.4.1.3. By End User
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Component
      • 7.2.4.2.2. By Cancer Type
      • 7.2.4.2.3. By End User

8. Europe AI in Cancer Diagnostics Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Cancer Type
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Component
      • 8.2.4.1.2. By Cancer Type
      • 8.2.4.1.3. By End User
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Component
      • 8.2.4.2.2. By Cancer Type
      • 8.2.4.2.3. By End User
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Component
      • 8.2.4.3.2. By Cancer Type
      • 8.2.4.3.3. By End User
      • 8.2.4.4. France
      • 8.2.4.4.1. By Component
      • 8.2.4.4.2. By Cancer Type
      • 8.2.4.4.3. By End User
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Component
      • 8.2.4.5.2. By Cancer Type
      • 8.2.4.5.3. By End User
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Component
      • 8.2.4.6.2. By Cancer Type
      • 8.2.4.6.3. By End User
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Component
      • 8.2.4.7.2. By Cancer Type
      • 8.2.4.7.3. By End User
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Component
      • 8.2.4.8.2. By Cancer Type
      • 8.2.4.8.3. By End User
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Component
      • 8.2.4.9.2. By Cancer Type
      • 8.2.4.9.3. By End User

9. Asia Pacific AI in Cancer Diagnostics Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Cancer Type
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Component
      • 9.2.4.1.2. By Cancer Type
      • 9.2.4.1.3. By End User
      • 9.2.4.2. India
      • 9.2.4.2.1. By Component
      • 9.2.4.2.2. By Cancer Type
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Component
      • 9.2.4.3.2. By Cancer Type
      • 9.2.4.3.3. By End User
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Component
      • 9.2.4.4.2. By Cancer Type
      • 9.2.4.4.3. By End User
      • 9.2.4.5. Australia & New Zealand
      • 9.2.4.5.1. By Component
      • 9.2.4.5.2. By Cancer Type
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Component
      • 9.2.4.6.2. By Cancer Type
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Component
      • 9.2.4.7.2. By Cancer Type
      • 9.2.4.7.3. By End User
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Component
      • 9.2.4.8.2. By Cancer Type
      • 9.2.4.8.3. By End User
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Component
      • 9.2.4.9.2. By Cancer Type
      • 9.2.4.9.3. By End User
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Component
      • 9.2.4.10.2. By Cancer Type
      • 9.2.4.10.3. By End User

10. Latin America AI in Cancer Diagnostics Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Cancer Type
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Component
      • 10.2.4.1.2. By Cancer Type
      • 10.2.4.1.3. By End User
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Component
      • 10.2.4.2.2. By Cancer Type
      • 10.2.4.2.3. By End User
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Component
      • 10.2.4.3.2. By Cancer Type
      • 10.2.4.3.3. By End User
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Component
      • 10.2.4.4.2. By Cancer Type
      • 10.2.4.4.3. By End User
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Component
      • 10.2.4.5.2. By Cancer Type
      • 10.2.4.5.3. By End User

11. Middle East & Africa AI in Cancer Diagnostics Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Million)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Cancer Type
    • 11.2.3. By End User
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Component
      • 11.2.4.1.2. By Cancer Type
      • 11.2.4.1.3. By End User
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Component
      • 11.2.4.2.2. By Cancer Type
      • 11.2.4.2.3. By End User
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Component
      • 11.2.4.3.2. By Cancer Type
      • 11.2.4.3.3. By End User
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Component
      • 11.2.4.4.2. By Cancer Type
      • 11.2.4.4.3. By End User
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Component
      • 11.2.4.5.2. By Cancer Type
      • 11.2.4.5.3. By End User
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Component
      • 11.2.4.6.2. By Cancer Type
      • 11.2.4.6.3. By End User
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Component
      • 11.2.4.7.2. By Cancer Type
      • 11.2.4.7.3. By End User
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Component
      • 11.2.4.8.2. By Cancer Type
      • 11.2.4.8.3. By End User

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global AI in Cancer Diagnostics Company Market Share Analysis, 2023
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

13. Global AI in Cancer Diagnostics Market: Import & Export

14. Impact of Escalating Geopolitical Tensions on Global AI in Cancer Diagnostics Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Ibex Medical Analytics
  • 15.2. Paige AI
  • 15.3. PathAI
  • 15.4. Tempus
  • 15.5. Freenome
  • 15.6. Enlitic
  • 15.7. CureMetrix
  • 15.8. Owkin
  • 15.9. DeepBio
  • 15.10. AIRA Matrix
  • 15.11. Indica Labs
  • 15.12. Mindpeak
  • 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable